Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients.


Journal

Cancer cell
ISSN: 1878-3686
Titre abrégé: Cancer Cell
Pays: United States
ID NLM: 101130617

Informations de publication

Date de publication:
08 02 2021
Historique:
received: 30 09 2020
revised: 02 12 2020
accepted: 30 12 2020
pubmed: 22 1 2021
medline: 23 2 2021
entrez: 21 1 2021
Statut: ppublish

Résumé

Given the immune system's importance for cancer surveillance and treatment, we have investigated how it may be affected by SARS-CoV-2 infection of cancer patients. Across some heterogeneity in tumor type, stage, and treatment, virus-exposed solid cancer patients display a dominant impact of SARS-CoV-2, apparent from the resemblance of their immune signatures to those for COVID-19

Identifiants

pubmed: 33476581
pii: S1535-6108(21)00001-5
doi: 10.1016/j.ccell.2021.01.001
pmc: PMC7833668
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

257-275.e6

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L006278/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L023091/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/T005106/1
Pays : United Kingdom

Informations de copyright

Crown Copyright © 2021. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare no competing interests.

Références

Transpl Infect Dis. 2014 Feb;16(1):165-9
pubmed: 24289829
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
Br J Haematol. 2010 Apr;149(1):3-13
pubmed: 20151975
J Pathol. 2015 Jan;235(2):185-95
pubmed: 25270030
Ann Rheum Dis. 2008 Jul;67(7):937-41
pubmed: 17981914
Lancet Oncol. 2020 Aug;21(8):1023-1034
pubmed: 32702310
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
Ann Rheum Dis. 2021 Jan;80(1):e10
pubmed: 32312768
Nature. 2020 Aug;584(7821):463-469
pubmed: 32717743
Cell Discov. 2020 May 4;6:31
pubmed: 32377375
Science. 2020 Aug 7;369(6504):643-650
pubmed: 32540902
N Engl J Med. 2020 Dec 3;383(23):2291-2293
pubmed: 33176080
J Natl Compr Canc Netw. 2020 Mar 20;:1-4
pubmed: 32197238
Cancer Discov. 2020 Jul 31;:
pubmed: 32737082
PLoS Pathog. 2020 Sep 24;16(9):e1008817
pubmed: 32970782
Annu Rev Immunol. 2019 Apr 26;37:457-495
pubmed: 30676822
Cell. 2020 Oct 1;183(1):158-168.e14
pubmed: 32979941
Br J Haematol. 2020 Sep;190(5):e279-e282
pubmed: 32526039
Lancet. 2020 Jun 20;395(10241):1919-1926
pubmed: 32473682
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
Blood. 2004 Feb 1;103(3):777-83
pubmed: 12907446
Cell Rep Med. 2020 Aug 25;1(5):100078
pubmed: 32838342
J Allergy Clin Immunol. 2020 Jul;146(1):119-127.e4
pubmed: 32360286
Commun Stat Appl Methods. 2015 Nov;22(6):665-674
pubmed: 26688802
Ann Oncol. 2020 Aug;31(8):1087-1088
pubmed: 32360743
Virology. 2013 Jan 5;435(1):37-45
pubmed: 23217614
Lancet. 2020 Jun 20;395(10241):1907-1918
pubmed: 32473681
Nat Microbiol. 2020 Dec;5(12):1598-1607
pubmed: 33106674
J Exp Med. 1998 Dec 21;188(12):2205-13
pubmed: 9858507
Cell. 2020 Dec 23;183(7):1901-1912.e9
pubmed: 33248470
BMC Immunol. 2008 Oct 17;9:59
pubmed: 18928527
Science. 2020 Sep 4;369(6508):
pubmed: 32669297
Hemasphere. 2020 Jul 30;4(4):e432
pubmed: 32803132
Nat Med. 2020 Oct;26(10):1623-1635
pubmed: 32807934
Leuk Lymphoma. 2013 Jul;54(7):1387-95
pubmed: 23240909
Lancet Infect Dis. 2020 Aug;20(8):e192-e197
pubmed: 32539990
J Exp Med. 1998 May 4;187(9):1383-93
pubmed: 9565631
Ecancermedicalscience. 2020 Mar 27;14:1022
pubmed: 32256705
JAMA. 2020 Apr 21;323(15):1488-1494
pubmed: 32125362
Front Oncol. 2020 Jul 22;10:1279
pubmed: 32903324
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Front Immunol. 2020 May 01;11:827
pubmed: 32425950
Ann Rheum Dis. 2020 Jul;79(7):859-866
pubmed: 32471903
Nat Med. 2020 May;26(5):672-675
pubmed: 32296168
Blood. 2020 Dec 17;136(25):2881-2892
pubmed: 33113551
Asian Pac J Allergy Immunol. 2020 Mar;38(1):1-9
pubmed: 32105090

Auteurs

Sultan Abdul-Jawad (S)

School of Cancer & Pharmaceutical Sciences, King's College London, London, UK.

Luca Baù (L)

Institute of Biomedical Engineering, University of Oxford, Oxford, UK.

Thanussuyah Alaguthurai (T)

School of Cancer & Pharmaceutical Sciences, King's College London, London, UK; Breast Cancer Now Research Unit, King's College London, London, UK.

Irene Del Molino Del Barrio (I)

Cancer Immunotherapy Accelerator, UCL Cancer Institute, University College and King's College, London, UK; Peter Gorer Department of Immunobiology, King's College London, London, UK.

Adam G Laing (AG)

Peter Gorer Department of Immunobiology, King's College London, London, UK.

Thomas S Hayday (TS)

Peter Gorer Department of Immunobiology, King's College London, London, UK.

Leticia Monin (L)

The Francis Crick Institute, London, UK.

Miguel Muñoz-Ruiz (M)

The Francis Crick Institute, London, UK.

Louisa McDonald (L)

Oncology and Haematology Clinical Trials (OHCT), Guy's and St Thomas' NHS Foundation Trust, London UK.

Isaac Francos Quijorna (I)

Wolfson Centre for Age-Related Diseases, IoPPN, King's College London, London, UK.

Duncan McKenzie (D)

The Francis Crick Institute, London, UK.

Richard Davis (R)

Peter Gorer Department of Immunobiology, King's College London, London, UK.

Anna Lorenc (A)

Peter Gorer Department of Immunobiology, King's College London, London, UK.

Julie Nuo En Chan (JNE)

School of Cancer & Pharmaceutical Sciences, King's College London, London, UK.

Sarah Ryan (S)

Department of Inflammation Biology, King's College London, London, UK.

Eva Bugallo-Blanco (E)

School of Cancer & Pharmaceutical Sciences, King's College London, London, UK.

Rozalyn Yorke (R)

Department of Inflammation Biology, King's College London, London, UK.

Shraddha Kamdar (S)

Peter Gorer Department of Immunobiology, King's College London, London, UK.

Matthew Fish (M)

Peter Gorer Department of Immunobiology, King's College London, London, UK; Department of Intensive Care Medicine, Guy's and St Thomas' NHS Foundation Trust, London, UK.

Iva Zlatareva (I)

Peter Gorer Department of Immunobiology, King's College London, London, UK.

Pierre Vantourout (P)

Peter Gorer Department of Immunobiology, King's College London, London, UK.

Aislinn Jennings (A)

Peter Gorer Department of Immunobiology, King's College London, London, UK; Department of Intensive Care Medicine, Guy's and St Thomas' NHS Foundation Trust, London, UK.

Sarah Gee (S)

Peter Gorer Department of Immunobiology, King's College London, London, UK.

Katie Doores (K)

Department of Infectious Diseases, King's College London, London, UK.

Katharine Bailey (K)

Department of Haematology, Guy's and St Thomas' NHS Foundation trust, London, UK.

Sophie Hazell (S)

Department of Haematology, Guy's and St Thomas' NHS Foundation trust, London, UK.

Julien De Naurois (J)

Department of Medical Oncology Guy's and St Thomas' NHS Foundation Trust, London, UK.

Charlotte Moss (C)

Department of Translational Oncology & Urology Research (TOUR), King's College London, London, UK.

Beth Russell (B)

Department of Translational Oncology & Urology Research (TOUR), King's College London, London, UK.

Aadil A Khan (AA)

Targeted Therapy Team, The Institute of Cancer Research, London, UK.

Mark Rowley (M)

London Institute for Mathematical Sciences, Mayfair, London, UK; Saddle Point Science Ltd, London, UK.

Reuben Benjamin (R)

School of Cancer & Pharmaceutical Sciences, King's College London, London, UK; Department of Haematological Medicine, King's College Hospital, London, UK.

Deborah Enting (D)

Department of Translational Oncology & Urology Research (TOUR), King's College London, London, UK.

Doraid Alrifai (D)

Department of Medical Oncology Guy's and St Thomas' NHS Foundation Trust, London, UK.

Yin Wu (Y)

School of Cancer & Pharmaceutical Sciences, King's College London, London, UK; Cancer Immunotherapy Accelerator, UCL Cancer Institute, University College and King's College, London, UK; Peter Gorer Department of Immunobiology, King's College London, London, UK; The Francis Crick Institute, London, UK.

You Zhou (Y)

Systems Immunity University Research Institute and Division of Infection and Immunity, Cardiff University, Cardiff, UK.

Paul Barber (P)

School of Cancer & Pharmaceutical Sciences, King's College London, London, UK.

Tony Ng (T)

School of Cancer & Pharmaceutical Sciences, King's College London, London, UK.

James Spicer (J)

School of Cancer & Pharmaceutical Sciences, King's College London, London, UK.

Mieke Van Hemelrijck (M)

Department of Translational Oncology & Urology Research (TOUR), King's College London, London, UK.

Mayur Kumar (M)

Department of Gastroenterology, Princess Royal University Hospital, Kent, UK.

Jennifer Vidler (J)

Department of Haematological Medicine, King's College Hospital, London, UK.

Yadanar Lwin (Y)

Department of Haematological Medicine, King's College Hospital, London, UK.

Paul Fields (P)

School of Cancer & Pharmaceutical Sciences, King's College London, London, UK; Department of Haematology, Guy's and St Thomas' NHS Foundation trust, London, UK.

Sophia N Karagiannis (SN)

Breast Cancer Now Research Unit, King's College London, London, UK; St. John's Institute of Dermatology, King's College London, London, UK; NIHR Biomedical Research Centre, and King's College London, London, UK.

Anthony C C Coolen (ACC)

Targeted Therapy Team, The Institute of Cancer Research, London, UK; London Institute for Mathematical Sciences, Mayfair, London, UK; Saddle Point Science Ltd, London, UK; Department of Biophysics, Radboud University, Nijmegen, The Netherlands.

Anne Rigg (A)

Department of Medical Oncology Guy's and St Thomas' NHS Foundation Trust, London, UK.

Sophie Papa (S)

School of Cancer & Pharmaceutical Sciences, King's College London, London, UK; Department of Medical Oncology Guy's and St Thomas' NHS Foundation Trust, London, UK.

Adrian C Hayday (AC)

Peter Gorer Department of Immunobiology, King's College London, London, UK; The Francis Crick Institute, London, UK.

Piers E M Patten (PEM)

School of Cancer & Pharmaceutical Sciences, King's College London, London, UK; Department of Haematological Medicine, King's College Hospital, London, UK; Medical Research Council (MRC) Clinical Academic Research Partnership, London, UK.

Sheeba Irshad (S)

School of Cancer & Pharmaceutical Sciences, King's College London, London, UK; Breast Cancer Now Research Unit, King's College London, London, UK; Department of Medical Oncology Guy's and St Thomas' NHS Foundation Trust, London, UK; Cancer Research UK (CRUK) Clinician Scientist, London, UK. Electronic address: sheeba.irshad@kcl.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH